Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) has received mixed analyst evaluations over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $168.74. The company shows strong revenue growth and net margin but faces challenges with return on equity.
September 09, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has received a range of analyst ratings, mostly somewhat bullish, with an increased average price target of $168.74. The company shows strong revenue growth and net margin but faces challenges with return on equity.
The majority of analysts are somewhat bullish on NBIX, with an increased average price target, indicating positive sentiment. The company's strong revenue growth and net margin are positive indicators, although challenges in ROE may temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100